Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBARQ-CSU LTE long-term extension study of barzolvolimab in chronic spontaneous urticaria
2025-522878-36-00Phase 3Authorised
- Sponsor
- Celldex Therapeutics
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 36
01
Overview
Phase 3, open-label trial of barzolvolimab in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Celldex Therapeutics. Primary endpoint: Time to disease worsening or treatment failure through Week 52. Planned start Apr 2026; status: authorised.
02
Drugs
barzolvolimab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2025-522878-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522878-36-00.